The activity of matrix metalloproteinases and the concentration of their tissue inhibitors in the blood serum of patients with type 2 diabetes mellitus, depending on the stage of compensation of the disease

The aim of the study was to test the hypothesis on the possible reason for the decrease in the activity of matrix metalloproteinases (MMPs) as a consequence of the high concentration of their tissue inhibitors (TIMPs) in the blood serum of patients with type 2 diabetes mellitus (T2DM). Material and methods. In the experimental part of the article, we used the blood serum of patients under observation in the clinic of the Federal Research Center of Fundamental and Translational Medicine. According to the content of glycated hemoglobin (HbA1С) in blood serum, the patients were divided into 3 groups: at the stage of compensation (6.0–6.5 % HbA1С), at the stage of subcompensation (6.6–7.0 % HbA 1С) and decompensation (> 7.0 % HbA1С). The activity of MMPs 2 and 7 in blood serum samples was measured by a fluorimetric method using a fluorescent substrate specific for these MMPs. The concentration of TIMP-1 (inhibitor of all non-membrane-bound MMPs) and TIMP-2 (active against MMP-2 and -7) in blood serum were determined by enzyme immunoassay. Results and discussion. In patients with T2DM, the MMP-2 and -7 activities decreased, more pronouncedly at the stage of decompensation. An increase in the concentration of TIMP-1 was observed in the serum of all patients, while no significant changes in the content of TIMP-2 were found. At the stage of decompensation, a decrease in MMP activity was accompanied by a decrease in the content of insulin, C-peptide and a corresponding increase in the level of proinsulin. An inverse correlation was found between the concentrations of TIMP-1 and insulin in patients at the stage of decompensation of T2DM. It is assumed that the activity of MMP-2 and -7, in comparison with their inhibitors, forms stronger correlations with the parameters of carbohydrate metabolism.

1. Kadoglou N.P., Liapis C.D. Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr. Med. Res. Opin. 2004;20(4):419–432. doi: 10.1185/030079904125003143

2. Fernandez-Patron C. Kassiri Z., Leung D. Modulation of systemic metabolism by MMP-2: from MMP- 2 deficiency in mice to MMP-2 deficiency in patients. Compr. Physiol. 2016;6(4):1935–1949. doi: 10.1002/cphy.c160010

3. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 2006;69(3):562–573. doi: 10.1016/j.cardiores.2005.12.002

4. Manello F., Medda V. Nuclear localization of matrix metalloproteinases. Prog. Histochem. Cytochem. 2012;47:27–58. doi: 10.1016/j.proghi.2011.12.002

5. Visse R., Nagase H. Мatrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function, and biochemistry. Circ. Res. 2003;92:827– 839. doi: 10.1161/01.RES.0000070112.80711.3D

6. Потеряева О.Н., Русских Г.С., Панин Л.Е. Анализ активности матриксных металлопротеиназ и α-1 протеиназного ингибитора в сыворотке крови больных сахарным диабетом 2 типа. Бюл. эксперим. биол. и мед. 2011;152(11):509–510. Poteryaeva O.N., Russkikh G.S., Panin L.E. Analysis of serum activities of matrix metalloproteinases and α1-proteinase inhibitor in patients with type 2 diabetes mellitus. Bull. Exp. Biol. Med. 2011;152(11):578–579. [In Russian].doi: 10.1007/s10517-012-1579-x

7. Hrabi A., Socha J.K., Sechman A. Involvement of matrix metalloproteinases (MMP-2, -7, -9) and their tissue inhibitors (TIMP-2, -3) in the regression of chicken postovulatory follicles. Gen. Comp. Endocrinol. 2018;260:32–40. doi: 10.1016/j.ygcen.2018.02.008

8. Nagase H., Karamanos N. Metalloproteinases in health and disease: challenges and the future prospects. FEBS J. 2011;278(1):1. doi: 10.1111/j.1742-4658.2010.07917.x

9. Потеряева О.Н., Русских Г.С., Зубова А.В., Геворгян М.М. Проинсулин – диагностический биохимический маркер декомпенсированного сахарного диабета 2-го типа. Клин. лаб. диагност. 2017;62(5):278–282. doi: 10.18821/0869-2084-2017-62-5-278-282 Poteryaeva O.N., Russkikh G.S., Zubova A.V., Gevorgyan M.M. Proinsulin is a diagnostic biochemical marker of type 2 decompensated diabetes mellitus. Klinicheskaya laboratornaya diagnostika = Russian Clinical Laboratory Diagnostics. 2017;62(5):278–282. [In Russian]. doi: 10.18821/0869-2084-2017-62-5-278-282

10. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–1495. doi: 10.2337/diacare.27.6.1487

11. Гланц С. Медико-биологическая статистика. М.: Практика, 1998. 459 с. Glantz S. Biomedical statistics. Moscow: Praktika, 1998. 459 p. [In Russian].

12. Потеряева О.Н., Русских Г.С., Панин Л.Е. Влияние липопротеинов высокой плотности на продукцию инсулина островками Лангерганса поджелудочной железы крыс и активность в них матриксных металлопротеаз. Междунар. ж. прикл. и фундам. исслед. 2011;5:78. Poteryaeva O.N., Russkikh G.S., Panin L.E. Influence of high density lipoproteins on insulin production by islets of Langerhans of the rat pancreas and the activity of matrix metalloproteases in them. Mezhdunarodnyy zhurnal prikladnykh i fundamental’nykh issledovaniy = International Journal of Applied and Basic Research. 2011;5:78. [In Russian].

13. Jazet I.M., Pijl H., Meinders A.E. Adipose tissue as an endocrine organ: impact on insulin resistance. Neth. J. Med. 2003;61(6):194–212.

14. Вельков В.В. Гликозилированный гемоглобин в диагностике сахарного диабета и в оценке рисков его осложнений. Клин.-лаб. консилиум. 2008;4(23):32–45. Velkov V.V. Glycosylated hemoglobin in the diagnosis of diabetes mellitus and in the assessment of the risks of its complications. Kliniko-laboratornyy konsilium = Clinical and Laboratory Consultation. 2008;4(23):32–45. [In Russian].

15. Żurawska-Płaksej E., Rorbach-Dolata A., Wiglusz K., Piwowar A. The effect of glycation on bovine serum albumin conformation and ligand binding properties with regard to gliclazide. Spectrochim. Acta. A. Mol. Biomol. Spectrosc. 2018;189:625–633. doi: 10.1016/j.saa.2017.08.071

16. Kuzan A., Michel O., Gamian A. Glycation of matrix proteins in the artery inhibits migration of smooth muscle cells from the media to the intima. Folia Biol. (Praha). 2017;63(3):105–114.

17. Peeters S.A., Engelen L., Buijs J., Theilade S., Rossing P., Schalkwijk C.G., Stehouwer C.D.A. Associations between advanced glycationendproducts and matrix metalloproteinases and its inhibitor in individuals with type 1 diabetes. J. Diabetes Complications. 2018;32(3):325–329. doi: 10.1016/j.jdiacomp.2017.12.011

18. Zhou P., Yang C., Zhang S., Ke Z.-X., Chen D.-X., Li Y.-Q., Li Q. The imbalance of MMP- 2/TIMP-2 and MMP-9/TIMP-1 contributes to collagen deposition disorder in diabetic non-injured skin. Front. Endocrinol. (Lausanne). 2021;12:734485. doi: 10.3389/fendo.2021.734485

19. Derosa G., Cicero A.F.G., Scalise F., Avanzini M.A., Tinelli C., Piccinni M.N., Peros E., Geroldi D., Fogari E., D’Angelo A. Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium. 2007;14(1):45–51. doi: 10.1080/10623320601177064

20. Kostov K., Blazhev A. Use of glycated hemoglobin (A1c) as a biomarker for vascular risk in type 2 diabetes: its relationship with matrix metalloproteinases-2 , -9 and the metabolism of collagen IV and elastin. Medicina. 2020;56(5):231. doi: 10.3390/medicina56050231

21. Kadoglou N.P., Daskalopoulou S.S., Perrea D., Liapis C.D. Matrix metalloproteinases and diabetic vascular complications. Angiology. 2005;56(2):173– 189. doi: 10.1177/000331970505600208